ORAMED PHARMACEUTICALS INC. (ORMP)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Revenues | - | - | - | |
| Cost of revenue | - | - | - | |
| Gross profit | - | - | - | |
| General and administrative expenses | 1,455 | 847 | 1,693 | |
| Research and development expenses | 1,034 | 2,242 | 1,442 | |
| Operating loss | -2,489 | -3,089 | -3,135 | |
| Financial income, net | 15,366 | -15,420 | 14,234 | |
| Interest expenses | - | - | 261 | |
| Other income, net | 257 | - | - | |
| Income before tax expenses | 13,134 | -18,509 | 10,838 | |
| Tax benefit (expenses) | -126 | 1,133 | 1,634 | |
| Net income | 13,260 | -19,642 | 9,204 | |
| Non-controlling interests | -28 | -23 | -8 | |
| Companys stockholders | 13,288 | -19,619 | 9,212 | |
| Basic income per share of common stock (in dollars per share) | 0.32 | -0.48 | 0.22 | |
| Diluted income per share of common stock (in dollars per share) | 0.31 | -0.48 | 0.22 | |
| Weighted average number of shares of common stock used in computing basic income per share of common stock (in shares) | 41,743,486 | 40,896,845 | 40,959,759 | |
| Weighted average number of shares of common stock used in computing diluted income per share of common stock (in shares) | 42,609,425 | 40,896,845 | 41,591,007 | |